摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-chloro-2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaen-10-ol trifluoroacetate | 1192323-40-2

中文名称
——
中文别名
——
英文名称
6-chloro-2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaen-10-ol trifluoroacetate
英文别名
6-Chloro-2,4,8,22-tetrazatetracyclo[14.3.1.13,7.19,13]docosa-1(19),3,5,7(22),9,11,13(21),16(20),17-nonaen-10-ol;2,2,2-trifluoroacetic acid
6-chloro-2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaen-10-ol trifluoroacetate化学式
CAS
1192323-40-2
化学式
C2HF3O2*C18H15ClN4O
mdl
——
分子量
452.82
InChiKey
ZKAICVVRKAXSJC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.05
  • 重原子数:
    31
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    107
  • 氢给体数:
    4
  • 氢受体数:
    10

文献信息

  • MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
    申请人:Combs Andrew Paul
    公开号:US20090286778A1
    公开(公告)日:2009-11-19
    The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    本发明涉及以下化学式I的大环化合物: 或其药用可接受盐或季盐,其中所述成员在此提供,并且它们的组成物和使用方法,这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用,例如炎症和自身免疫性疾病以及癌症。
  • US8871753B2
    申请人:——
    公开号:US8871753B2
    公开(公告)日:2014-10-28
  • [EN] MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS<br/>[FR] COMPOSÉS MACROCYCLIQUES ET LEUR UTILISATION À TITRE D'INHIBITEURS DE KINASE
    申请人:INCYTE CORP
    公开号:WO2009132202A2
    公开(公告)日:2009-10-29
    The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
查看更多